Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
HHS to allow US pharmacies to sell six FDA-unapproved peptides — Fortune
An HHS policy could allow US compounding pharmacies to sell six FDA-unapproved peptides despite unresolved safety and efficacy concerns.
Pfizer Ends Premarin Hormone Therapy Sales in Canada After Internal Review
Pfizer is ending Premarin cream and tablet sales in Canada after an internal review, with remaining tablet supplies expected to last until mid-2027.
FDA Approves Bayer's Asundexian Pill to Lower Recurrent Stroke Risk by 26%
The FDA approved Bayer’s Sunharbo (asundexian) after trial data showed a 26% lower relative risk of recurrent ischemic stroke with antiplatelets.
Takeda Launches Orzeyful for Narcolepsy After Rapid DEA Schedule IV Review
Takeda launches Orzeyful (oveporexton) for narcolepsy type 1 in the US after a rapid DEA review grants the oral drug Schedule IV classification.
Neuroimplant Trial Participants Demand More Rights, Fewer Restrictions
Brain implant trial participants urge limits on NDAs, stronger neural data privacy and support for users after neurointerface studies end.
FDA's Priority Review Voucher Program Faces Uncertainty After Makary Exit
Reports suggest the FDA's priority voucher scheme may be discontinued following scrutiny of its selection process, while HHS says the pilot continues.
NervGen's NVG-291 Wins FDA Breakthrough Therapy Designation for SCI Drug
The FDA granted Breakthrough Therapy designation to NervGen's NVG-291 for chronic cervical spinal cord injury as its Phase 3 RESTORE trial enrolls.
Monte Rosa Reports MRT-8102 Preclinical Data for Gout Inflammation Study
Monte Rosa reports that NEK7 degrader MRT-8102 reduced inflammatory markers and joint swelling in preclinical gout models, ahead of planned Phase 2 testing.
Wistar Study Links Fructose Signaling to Ovarian Cancer Spread After Chemo
Wistar researchers report that fructose released by chemotherapy-surviving ovarian cancer cells may weaken cell connections and aid tumor spread.
Michael Bisping Backs Xycota's Low-Dose Psilocybin PTSD Research Program
UFC veteran Michael Bisping supports Xycota's preclinical XYCO-02 research on low-dose psilocybin for PTSD, with safety and efficacy still unproven.
Johnson & Johnson Reports 73% PSA Response with Pasritamig Combination
Johnson & Johnson reports 73% of evaluable patients achieved at least 50% PSA reduction with pasritamig and JNJ-9401 in a Phase 1 prostate cancer study.
Boehringer Plans Survodutide Filing Following Positive Cardiac Safety Data
Boehringer Ingelheim plans regulatory submissions after Phase III survodutide data showed cardiovascular safety and weight loss in adults with obesity.
1
2
3
4
5